Clinical Trial to Evaluate the Tolerance of TQB2210 Injection

CTTQ

Status and phase: Enrolling; Phase 1

Conditions: Advanced Malignant Tumours

Treatments: Drug: TQB2210 Injection

Study type: Interventional

Funder types: Industry

Identifiers

NCT06929195

TQB2210-I-01

Details and patient eligibility

About

TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity and inhibit tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor. The aim of this experiment is to evaluate the tolerability, pharmacokinetics, and preliminary efficacy of TQB2210 injection in patients with advanced malignant tumors, and to assess its effectiveness and phase II recommended dose (RP2D) in advanced malignant tumors with FGFR2b overexpression, such as advanced gastric/gastroesophageal junction cancer.

Enrollment: 90 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG-PS), score: 0-1; The expected survival time is more than 3 months.
• At least one tumour lesion that can be evaluated according to Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 in the dose-escalation phase and at least one measurable lesion in the dose-expansion phase.
• Good function of major organs.
• Patients with advanced malignant tumours confirmed by histology or cytology, disease progression or intolerance after adequate standard treatment, lack of standard treatment options.
• Can provide tumor tissue specimens collected fresh or sliced within 6 months (preserved in wax blocks collected within 3 years) for further detection for FGFR2b expression
• Fertile subjects should agree that contraception must be used during the study and for 6 months after the end of the study; Women of childbearing age had a negative serum pregnancy test within 7 days prior to study enrollment and had to be non-lactating subjects.
• Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.

Exclusion criteria

• Has had or is currently suffering from other malignant tumors

• There are diseases that affect intravenous injection and venous blood collection

• Adverse reactions from previous treatments have not recovered to CTCAE v5.0 Grade 1

• Received major surgical treatment, significant traumatic injury within 4 weeks prior to the first dose of TQB2210, or exist long-term unhealed wounds or fractures

• Subjects who experience any bleeding or bleeding events ≥ CTCAE grade 3 within 4 weeks prior to the first dose of TQB2210

• An arterial/venous thrombotic event occurred within 6 months prior to to the first dose of TQB2210

• Patients with active viral hepatitis that is poorly controlled

• Active syphilis patients requiring treatment

• A history of active pulmonary tuberculosis, idiopathic pulmonary fibrosis, institutional pneumonia, drug-induced pneumonitis/radiation pneumonia requiring treatment or active pneumonia with obvious clinical symptoms, interstitial pneumonia requiring treatment

• Subjects with any severe and/or uncontrolled illnesses

• Individuals who are preparing for or have previously undergone allogeneic bone marrow transplantation or solid organ transplantation

• History of hepatic encephalopathy

• Suffering from significant cardiovascular disease

• Active or uncontrolled severe infections

• Patients with renal failure requiring hemodialysis or peritoneal dialysis;

• Corneal defects, corneal ulcers, keratitis or keratoconus, history of corneal transplantation, or other known corneal abnormalities that may increase the risk of developing corneal ulcers within 6 months prior to the first treatment or currently present

• History of retinal disease or retinal detachment, or increased risk of retinal detachment according to the opinion of an ophthalmologist

• Acute ophthalmic diseases that continue to progress within the first 4 weeks of enrollment

• Unwilling to avoid using contact lenses during research treatment

• History of immunodeficiency, includingHuman Immunodeficiency Virus（HIV） positivity or other acquired or congenital immunodeficiency diseases

• There are poorly controlled autoimmune diseases that require the use of immunosuppressants or systemic hormone therapy to achieve immunity Subjects who inhibit the purpose and need to continue using it within 7 days before the first administration

• Individuals with epilepsy who require treatment

• Poor control of diabetes

• Tumor related symptoms and treatment:

  1. Received chemotherapy, immunotherapy, small molecule targeted drugs, etc. within 3 weeks before the first administration;
  2. Traditional Chinese patent medicines and simple preparations with anti-tumor indications specified in the National Medical Products Administration (NMPA )approved drug directions within 1 week before the first drug use;
  3. Imaging (Computed Tomography or Magnetic Resonance Imaging) shows that the tumor has invaded important blood vessels, or the researcher has determined that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during subsequent studies;
  4. Uncontrolled pleural effusion, pericardial effusion, or moderate to severe ascites that still require repeated drainage;
  5. Known to have spinal cord compression, meningeal metastasis/malignant meningitis, accompanied by symptoms of brain metastasis, or symptoms/imaging control time less than 4 weeks. Within 2 weeks before the start of treatment, steroid therapy or dehydration agents are still required;
  6. For non-small cell lung cancer subjects known to have meaningful gene mutations such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) fusion, ROS Proto-Oncogene 1, Receptor Tyrosine Kinase (ROS) fusion, etc., they should have received corresponding targeted therapy;
  7. Subjects with known human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction cancer and breast cancer should have received corresponding anti HER2 treatment;

• Known to be allergic to research drug excipient components

• Previously received targeted FGFR2b monoclonal antibod therapy

• Previously received chemotherapy drugs used in the protocol (limited to subjects receiving combination therapy during the dose escalation phase only)

• Individuals who have participated in and used other anti-tumor clinical trial drugs within 4 weeks prior to their first medication.

• According to the judgment of the researchers, there are situations that seriously endanger the safety of the subjects or affect their ability to complete the study

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

90 participants in 1 patient group

TQB2210 Injection

Experimental group

Description:

Dose escalation experiment: Intravenous infusion once of TQB2210 for injection every two weeks, 28 days as one treatment cycle. (1.0 mg/kg, 3.0 mg/kg, 8.0 mg/kg, 16.0 mg/kg, 24.0 mg/kg) Dose expansion experiment: Chose one or two appropriate dose groups in the dose escalation experiment to amplify.

Treatment:

Drug: TQB2210 Injection